SCHEMBL2931072

SCHEMBL2931072

CCN(CC)c1ccc2[nH]c(Nc3ccccc3C(C)C)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPT P10636 8/20 0.44
NPSR1 Q6W5P4 6/20 0.44
LMNA P02545 6/20 0.44
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
HTT P42858 4/20 0.44
NPC1 O15118 4/20 0.44
KDM4E B2RXH2 3/20 0.44
HPGD P15428 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
GAA P10253 2/20 0.44
POLB P06746 2/20 0.44
RAB9A P51151 6/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
TP53 P04637 2/20 0.40
TERT O14746 1/20 0.40
USP2 O75604 2/20 0.38
GPR35 Q9HC97 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2932290 0.91 MAPT (0.47) SMN1; SMN2ALDH1A1MAPTNPSR1LMNA
SCHEMBL14693663 0.79 GAA (0.61) SMN1; SMN2ALDH1A1MAPTNPSR1LMNA
SCHEMBL14693664 0.78 DDX3X (0.39) SMN1; SMN2ALDH1A1MAPTLMNAMEN1
SCHEMBL14693654 0.78 DDX3X (0.39) SMN1; SMN2ALDH1A1MAPTLMNAMEN1
SCHEMBL2932965 0.77 MAPT (0.41) SMN1; SMN2ALDH1A1MAPTNPSR1LMNA
SCHEMBL2932568 0.76 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1MAPTNPSR1LMNA
SCHEMBL2927773 0.76 AKR1C3 (0.51) SMN1; SMN2ALDH1A1MAPTNPSR1LMNA
SCHEMBL2933172 0.75 RIPK1 (0.53) SMN1; SMN2ALDH1A1MAPTLMNAMEN1
SCHEMBL2931975 0.75 TERT (0.44) SMN1; SMN2ALDH1A1MAPTNPSR1LMNA
SCHEMBL2930141 0.74 RAB9A (0.44) SMN1; SMN2ALDH1A1MAPTNPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820821-B2 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors TRANSTECH PHARMA, INC. (US) 2010-10-26 US disclosed
US-20100152170-A1 Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors TRANSTECH PHARMA, INC. (US) 2010-06-17 US disclosed
US-20070219235-A1 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors VTVX HOLDINGS I LLC 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152170-A1 Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors AURKC, AURKA, AURKB SMN1; SMN2 4734/4885ALDH1A1 3036/4885MAPT 1464/4885
US-20070219235-A1 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors AURKC, AURKA, AURKB SMN1; SMN2 4734/4885ALDH1A1 3036/4885MAPT 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.